Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2004-08-16
2008-10-28
Rawlings, Stephen L (Department: 1643)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S023500, C536S024310, C435S325000, C530S350000
Reexamination Certificate
active
07442543
ABSTRACT:
A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.
REFERENCES:
patent: 5356817 (1994-10-01), Cole
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: WO 98-42738 (1998-10-01), None
patent: WO 99/51637 (1999-10-01), None
Korotkov et al. (J. Biol. Chem. May 4, 2001; 276 (18): 15330-15336).
Bowie et al. (Science 1990; 257: 1306-1310).
Burgess et al. (Journal of Cell Biology 1990; 111: 2129-2138).
Lazar et al. (Molecular and Cellular Biology, 1988, 8: 1247-1252).
Luque et al. (Biochemistry. Nov. 19, 2002; 41 (46): 13663-13671).
Vucic et al. (J. Biol. Chem. Dec. 18, 1998; 273 (51): 33915-33921).
Takada et al. (Mol. Endocrinol. 2000; 14 (5): 733-740).
Guo et al. (Proc. Natl. Acad. Sci. USA. Jun. 22, 2004; 101 (25): 9205-9210).
Gura (Science. 1997; 278: 1041-1042).
Verma et al. (Nature 1997, 389: 239-242).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Pandha et al. (Current Opinion in Investigational Drugs 2000; 1 (1): 122-134).
Houdebine (Journal of Biotechnology 1994, 34: 269-287).
Boehringer Mannheim Biochemicals, 1994 Catalog (No. 1034 731/1006 924), p. 93.
Zhang et al. (Proc. Natl. Acad. Sci. USA. Jul. 1, 1992; 89 (13): 5847-5851).
Hu et al. (Cancer Res. Mar. 1, 2001; 61 (5): 2307-2310).
Labunskyy et al. (J. Biol. Chem. Nov. 11, 2005; 280 (45): 37839-37845).
Novoselov et al. (Biochem. J. Mar. 15, 2006; 394 (Pt 3): 575-579).
Labunskyy et al. (IUBMB Life. Jan. 2007; 59 (1): 1-5).
Calvo et al., “Alterations in Gene Expression Profiles During Cancer Progression: Functional Correlations to Tumorigenicity and Down-Regulation of Selenoprotein-P in Mouse and Human Tumors,”Cancer Res. 62: 5325-5335, 2002.
Clark et al., “Effects of Selenium Supplementation for Cancer Prevention in Patients with Carcinoma of the Skin: A Randomized Controlled Trial”JAMA, 276(24), 1957-1963, 1996.
De Plaen et al., “Structure, Chromosomal Localization, and Expression of 12 Genes of theMAGEFamily,”Immunogenetics40: 369-369, 1994.
Early et al., “Selenoprotein Levels in Patients With Colorectal Adenomas and Cancer,”Am. J. Gastroenterol. 97(3): 745-748, 2002.
Gail, “Some Statistical Methods for Immunodiagnostic Cancer Tests,”Immunol. Ser. 53: 13-25, 1990.
Gamble et al., “Selenium-dependent Gluththione Peroxidase and other Selenoproteins: Their Synthesis and Biochemcial Roles”J. Chem. Tech. Biotechnol., 68: 123-134, 1997.
Gladyshev et al., “A New Human Selenium-containing Protein: Purification, Characterization, and cDNA Sequence”J. Biol. Chem. 273(15):8910-8915, 1998.
Gladyshev et al., “Selenium in Normal and HIV-Infected Human T Cells: Discovery of a Novel Selenoprotein”FASEB J. 11(3): A235, 1997.
Gladyshev et al., “Contrasting Patterns of Regulation of the Antioxidant Selenoproteins, Thioredoxin Reductase, and Glutathione Peroxidase, in Cancer Cells,”Biochem. Biophys. Res. Comm. 251: 488-493, 1998.
Kote-Jarai et al., “Association Between the GCG Polymorphism of the Selenium DependentGPX1Gene and the Risk of Young Onset Prostate Cancer,”Prostate Cancer and Prostatic Diseases5: 189-192, 2002.
Kumaraswamy et al., “Structure-Expression Relationships of the 15-kDa Selenoprotein Gene,”J. Biol. Chem. 275(45): 35540-35547, 2000.
Li et al., “Isoform-Specific Expression of VEGF-B in Normal Tissues and Tumors,”Growth Factors19: 49-59, 2001.
Mörk et al., “Inverse MRNA Expression of the Selenocysteine-Containing Proteins GI-GPx and SeP in Colorectal Adenomas Compared With Adjacent Normal Mucosa,”Nutr. Cancer37(1): 108-116, 2000.
Proia, “Gene encoding the human β chain: Extensive homology of intron placement in the α- and β-chain genes”Proc. Natl. Acad. Sci. USA85: 1883-1887, 1988.
Rae et al., “Novel Association of a Diverse Range of Genes Renal Cell Carcinoma as Identified by Differential Display,”Int. J. Cancer88: 726-732, 2000.
Skolnick and Fetrow, “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,”TIBTECH18: 34-39, 2000.
Tockman et al., “Considerations in Bringing a Cancer Biomarker to Clinical Application,”Cancer Res.(Suppl.) 52: 2711s-2718s, 1992.
Ward, “Tumour Markers,”Dev. Oncol. 21: 90-106, 1985.
Diamond Alan
Gladyshev Vadim N.
Hatfield Dolph L.
Jeang Kuan-Teh
Wootton John C.
Klarquist & Sparkman, LLP
Rawlings Stephen L
The Board of Trustees of the University of Illinois
The United States of America as represented by the Department of
LandOfFree
Mammalian selenoprotein differentially expressed in tumor cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian selenoprotein differentially expressed in tumor cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian selenoprotein differentially expressed in tumor cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4016567